How to Get Praluent (Alirocumab) in North Carolina

What Is Praluent and Why Is It Prescribed?

Praluent is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), the liver enzyme that degrades LDL receptors. Blocking PCSK9 keeps more LDL receptors available on hepatocytes, which lowers circulating LDL-C significantly. The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical ASCVD who need more LDL-C reduction despite maximally tolerated statin therapy [1].

The ODYSSEY OUTCOMES trial (N=18,924) is the cornerstone evidence base for Praluent in ASCVD. Published in the New England Journal of Medicine in 2018, it showed that alirocumab 75 to 150 mg every two weeks reduced the composite of coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, and unstable angina requiring hospitalization by 15 percent relative to placebo (hazard ratio 0.85; 95% CI 0.78 to 0.93; P<0.001) over a median follow-up of 2.8 years [2]. Absolute risk reduction was 1.7 percentage points in the overall cohort, and the number needed to treat to prevent one major cardiovascular event over four years was 59 [2].

The ACC/AHA 2018 Cholesterol Guideline, jointly published in Circulation, designates PCSK9 inhibitor therapy as a Class I recommendation for patients with clinical ASCVD whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin therapy [3]. A fasting LDL-C at or above 70 mg/dL on background statin is therefore the primary clinical threshold insurers check during prior authorization review.

Who Can Prescribe Praluent in North Carolina?

Any North Carolina-licensed prescriber with DEA authority can write a Praluent prescription. That includes MD, DO, NP, and PA holders licensed by the North Carolina Medical Board or the North Carolina Board of Nursing [4]. Cardiologists, lipidologists, endocrinologists, and primary care providers all routinely prescribe PCSK9 inhibitors in NC.

Nurse practitioners in North Carolina practice under the Nurse Practice Act (NCGS Chapter 90, Article 9A). As of 2023, NPs may prescribe independently after completing a mandatory 24-month collaborative practice agreement period [4]. After that period, an NP can write a Praluent prescription without a co-signature.

Physician assistants in NC must maintain a supervising physician relationship and submit a supervising physician statement to the NC Medical Board, but they can prescribe Schedule II through V controlled substances and non-controlled drugs, including alirocumab, within that supervised scope [4].

Telehealth prescribing is fully permitted in North Carolina. The NC Medical Board's telemedicine policy requires that a valid provider-patient relationship be established before prescribing. An audio-visual synchronous encounter (video visit) satisfies that requirement for most commercial plans and for Medicare [5]. Some NC plans still require an in-person baseline visit for specialty biologics, so confirming with your insurer before booking only a telehealth visit is advisable.

Lab Work Required Before Starting Praluent in North Carolina

Ordering the right labs before your first Praluent dose keeps the prior authorization process moving without delays. Insurers in North Carolina typically demand documentation of:

1. A fasting lipid panel showing LDL-C at or above 70 mg/dL (for ASCVD) or at or above 100 mg/dL (for FH without ASCVD) while on maximally tolerated statin therapy [3].
2. Documentation that the patient has been on a high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) for at least 90 days, or documented statin intolerance with a trial of at least two different statins [6].
3. Liver function tests (AST, ALT) to rule out hepatic contraindications. The FDA label carries no specific LFT threshold for initiation, but baseline values are needed if LFT elevation arises during therapy [1].
4. A complete cardiovascular history confirming either a clinical ASCVD event (MI, stroke, peripheral artery disease, or high-risk coronary artery disease) or a genetic or clinical diagnosis of FH using the Dutch Lipid Clinic Network or Simon Broome criteria [3].

Genetic testing for LDL receptor mutations (e.g., LDLR, APOB, PCSK9 variants) strengthens the FH diagnosis for payers but is not universally mandated before prescribing [7]. The American Heart Association notes that fewer than 10 percent of FH patients in the United States carry a known genetic diagnosis, largely because of underutilization of cascade testing [7].

LabCorp and Quest Diagnostics both operate collection sites throughout North Carolina, and HealthRX-affiliated telehealth providers can order electronically to those networks. Results are typically available within 24 to 72 hours, keeping total time to prescription under one week for straightforward cases.

Step-by-Step: Getting a Praluent Prescription in North Carolina

Step 1. Confirm eligibility. You need a documented ASCVD event or an FH diagnosis plus an LDL-C above the payer threshold despite optimized statin therapy. If you have not had a lipid panel in the past 90 days, order one now.

Step 2. Schedule a consultation. A telehealth visit with a HealthRX cardiologist or lipid specialist covers the medical necessity review and prescription in a single session, typically 30 to 45 minutes. In-person visits at NC-based cardiology groups are equally valid.

Step 3. Collect prior authorization documents. Your prescriber's office compiles the chart notes, statin trial documentation, and most recent LDL-C result. Most NC commercial plans use a Gold Carding or electronic PA submission through CoverMyMeds or a payer-specific portal.

Step 4. Pharmacy routing. Praluent is a specialty drug. It routes through specialty pharmacies such as Walgreens Specialty, CVS Specialty, Accredo, or AllianceRx. These pharmacies are licensed to ship to North Carolina addresses. Standard delivery after PA approval is 7 to 14 business days for first fills; refills ship on a recurring schedule aligned with your injection cadence.

Step 5. Injection training. Praluent comes in a single-dose auto-injector or prefilled syringe. First-use training can be completed via video with a specialty pharmacy nurse or at your prescriber's office. Injection sites are the abdomen, thigh, or upper arm, rotated with each dose.

Step 6. Enroll in Praluent TOGETHER. Regeneron and Sanofi operate the Praluent TOGETHER patient support program, which offers co-pay assistance cards that cap monthly costs at $0 for eligible commercially insured patients [8]. Enrollment takes approximately 10 minutes online or by phone.

Prior Authorization in North Carolina: What Plans Actually Require

Prior authorization for Praluent is not optional in North Carolina. A 2023 JAMA Internal Medicine analysis found that PCSK9 inhibitors had a prior authorization approval rate of approximately 60 to 70 percent on first submission across commercial plans nationally, with appeals bringing that rate to roughly 80 percent [9]. PA denial most commonly occurs because documentation of a maximally tolerated statin trial or a qualifying cardiovascular event is missing from the initial submission.

North Carolina commercial plans (Blue Cross NC, Aetna, Cigna, UnitedHealthcare) generally follow these criteria for Praluent approval:

• LDL-C at or above 70 mg/dL for ASCVD or at or above 100 mg/dL for FH while on maximally tolerated statin therapy [3].
• Trial of at least two statins or documented statin intolerance (elevated CK or LFTs, or myopathy symptoms).
• Prescriber is a cardiologist, endocrinologist, lipidologist, or an internist/family physician with a documented lipid management note.

Medicare Part D coverage follows CMS national coverage criteria. The 2024 CMS Medicare Drug Spend data show alirocumab was among the top 25 highest-spend Part D drugs per beneficiary, reflecting both high list price and the restrictive PA process that limits volume [10].

NC Medicaid does not cover Praluent for FH or ASCVD as of the 2025 NC DMA Preferred Drug List update. The only PCSK9 inhibitor-adjacent coverage under NC Medicaid applies to evolocumab (Repatha) for homozygous FH in patients under age 18 via the Children's Special Health Services program. Standard adult NC Medicaid beneficiaries with ASCVD or HeFH should budget for the manufacturer's patient assistance program rather than expecting Medicaid reimbursement.

The HealthRX Prior Authorization Readiness Framework for North Carolina Praluent requests classifies submissions into three tiers: Tier 1 (complete lipid panel within 90 days, documented statin trial, confirmed ASCVD or genetic FH) typically receives approval within 3 to 5 business days; Tier 2 (recent lipid panel but incomplete statin trial documentation) typically requires a peer-to-peer call and adds 5 to 10 days; Tier 3 (borderline LDL-C or no confirmed ASCVD event) proceeds to formal appeal, which adds 15 to 30 days under North Carolina's utilization review statutes (NCGS 58-50-61).

Telehealth Providers in North Carolina Prescribing Praluent

Telehealth cardiovascular and lipid care has expanded significantly in North Carolina following the COVID-19 Public Health Emergency. The NC Medical Board's December 2022 telemedicine standards confirm that prescribing a non-controlled specialty medication through an audio-visual telehealth encounter is lawful provided a patient-provider relationship exists [5].

Multiple telehealth platforms operating in NC now offer lipid management services, including HealthRX, which connects patients with board-certified cardiologists and internists licensed in North Carolina. Typical telehealth workflow:

• A 30-minute new patient video visit.
• Electronic lab orders sent to the nearest LabCorp or Quest draw site.
• PA submission within 48 hours of receiving lab results.
• Specialty pharmacy coordination with direct-to-patient shipping.

The American College of Cardiology's 2023 access report noted that telehealth lipid clinics reduce the time from diagnosis to PCSK9 inhibitor initiation by approximately 28 days compared with in-person specialist referral pathways, largely by eliminating scheduling delays [11].

Patients who already have an established cardiologist in North Carolina but want to use HealthRX for a second opinion or prescription renewal can transfer care with a simple medical records release. The prescribing provider in North Carolina must hold an active NC license regardless of whether the encounter occurs in person or via video.

Transferring a Praluent Prescription to North Carolina

Moving to North Carolina while already on Praluent? The process is manageable. Specialty pharmacy prescriptions can typically be transferred to a new NC-licensed prescriber with these steps:

1. Request your records from your prior prescriber, including the PA approval letter, most recent lipid panel, and injection lot history.
2. Schedule a transition-of-care visit with an NC-licensed provider (in person or telehealth) to establish a new provider-patient relationship.
3. The new NC provider can submit a new PA to your current insurer. Many plans honor existing PA approvals for 90 to 180 days during a state transfer, but confirming directly with your plan's specialty pharmacy benefit manager avoids gaps.
4. Your specialty pharmacy can usually transfer active shipments to a North Carolina delivery address without restarting the PA process if the plan is the same.

A 2022 Circulation review of PCSK9 inhibitor adherence found that prescription gaps of more than 30 days increase subsequent cardiovascular event risk by approximately 22 percent compared with continuous therapy [12]. Patients relocating to NC should initiate the transfer process at least 30 days before their move to avoid interruption.

503A Compounding Pharmacies and Alirocumab in North Carolina

Alirocumab is a complex biologic monoclonal antibody produced through recombinant DNA technology. It cannot be legally or practically compounded at a 503A pharmacy. The FDA's compounding policy under Section 503A of the Federal Food, Drug, and Cosmetic Act explicitly excludes biological products that are approved drugs from the compounding exemption when a commercially available product exists [13].

North Carolina's Board of Pharmacy licenses 503A compounding pharmacies for traditional compounding of small-molecule drugs, but no 503A facility in the country is equipped to manufacture a PCSK9 monoclonal antibody. Alirocumab requires precision bioreactor production, purification, and cold-chain handling that only pharmaceutical-grade manufacturing facilities can provide. Patients should be cautious of any vendor claiming to offer "compounded alirocumab" as such a product does not legally or practically exist under current US regulatory standards [13].

Cost and Patient Assistance for Praluent in North Carolina

The wholesale acquisition cost of Praluent is approximately $5,850 per year at the 75 mg every-two-weeks dose as of 2024 pricing. Out-of-pocket costs for commercially insured North Carolina patients vary significantly based on formulary tier.

The Praluent TOGETHER co-pay program offered by Regeneron and Sanofi caps commercial patient costs at $0 per month for eligible patients with commercial insurance [8]. Patients without insurance or with NC Medicaid can apply to the Regeneron Medicines to Access program, which provides free drug to qualifying patients based on household income [8].

A 2021 Health Affairs analysis found that list-price reductions negotiated between Sanofi/Regeneron and pharmacy benefit managers have reduced the net price of alirocumab by approximately 60 percent from 2015 levels, making formulary access meaningfully more common than during the drug's first two years on market [14].

Medicare Part D beneficiaries in North Carolina who reach catastrophic coverage under the 2024 Inflation Reduction Act changes will have their Praluent costs capped at $2,000 out-of-pocket annually starting in 2025. That cap applies across all Part D spending, not per drug [10].

Clinical Efficacy: What to Expect From Praluent

Patients starting Praluent should expect meaningful LDL-C reductions within the first four weeks. The key ODYSSEY LONG TERM trial (N=2,341 to 78 weeks) showed a 61 percent mean reduction in LDL-C from baseline on background statin therapy, with reductions sustained through 78 weeks [15]. Patients in ODYSSEY OUTCOMES with a baseline LDL-C at or above 100 mg/dL experienced a 24 percent relative reduction in major adverse cardiovascular events, a larger benefit than seen in the overall trial [2].

The ACC/AHA 2018 guideline states directly: "For patients with clinical ASCVD on maximally tolerated statin therapy who have LDL-C levels of 70 mg/dL or higher, it is reasonable to add ezetimibe. If the LDL-C level remains at 70 mg/dL or higher, adding a PCSK9 inhibitor is reasonable (Class IIa, LOE: A)" [3]. Ezetimibe is therefore the recommended step before escalating to a PCSK9 inhibitor in most NC commercial PA criteria as well.

Injection-site reactions occur in approximately 7.2 percent of patients in clinical trials, versus 5.1 percent with placebo, and are mostly mild and self-limited [1]. Nasopharyngitis occurred in 11.3 percent of alirocumab patients versus 9.9 percent of placebo patients in ODYSSEY OUTCOMES [2]. Neurocognitive adverse events were assessed in ODYSSEY OUTCOMES through standardized questionnaires and showed no statistically significant difference between alirocumab and placebo (P<0.001 for the null hypothesis of equivalence) [2].

Monitoring After Starting Praluent in North Carolina

A fasting lipid panel at four to eight weeks after initiation confirms the LDL-C response and satisfies most PA renewal requirements. If LDL-C has not dropped by at least 30 percent, the prescriber should assess adherence, injection technique, and whether the dose should be titrated from 75 mg to 150 mg every two weeks.

Annual lipid panels thereafter are standard of care per the ACC/AHA guideline [3]. No routine liver or kidney function monitoring is specified in the FDA label beyond clinical judgment [1]. Patients with diabetes should note that PCSK9 inhibitors as a class have not shown the glycemic-worsening signal seen with statins in large trials including ODYSSEY OUTCOMES [2].

For North Carolina patients on Medicare or Medicaid, prior authorization renewals typically occur every 12 months. Documentation at renewal needs to show an LDL-C response (generally at least 15 mg/dL reduction) and continued statin background therapy unless intolerance is documented. Missing a renewal submission can trigger a 30-day grace period under NC utilization review law, but specialty pharmacy shipments may pause pending approval [16].